IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Hepatitis A Vaccination in the Elderly
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A lot of elderly people travel to hepatitis A endemic areas. The prevalence of hepatitis A IgG positivity is declining in the Netherlands, also in the elderly. Studies show that people above 40 years of age have a slower immune response to hepatitis A vaccination. However, a lot of travelers seek pre-travel advice only shortly before their journey. More information about the time to adequate antibody response after hepatitis A vaccination is required to provide good protection during travelling. Alternative protection with immunoglobulins are available.
Study design: Observational, longitudinal pilot study Study population: 20 adults over 60 years of age with a negative hepatitis A IgG, (with a estimated 50% positivity for hepatitis A IgG in this age Group, 40 patients in this age group) 20 adults 18-40 years of age as controls.
Intervention (if applicable): When hepatitis A vaccination is indicated and informed consent is obtained, hepatitis A IgG wil be measured at day 0, 7, 14, 21 en 28.
Main study parameters/endpoints: Time to protective hepatitis A IgG. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: hepatitis A vaccination will be given also outside this study. In the study 5 venous punctures of 7 ml of blood.
| Condition |
|---|
| Hepatitis A |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Hepatitis A Vaccination in the Elderly |
- How fast do patients> 60 year reach protective anti-HAV levels after vaccination? [ Time Frame: 0, 1,2,3,4 weeks ]
Biospecimen Retention: Samples With DNA
| Enrollment: | 60 |
| Study Start Date: | July 2010 |
| Study Completion Date: | July 2015 |
| Primary Completion Date: | July 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| >60 years |
| < 40 years |
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Exclusion Criteria:
- previous hep A vaccination
- known hepatitis A serology status
- immunodeficiency
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01353989
| Netherlands | |
| Rijnstate Hospital | |
| Arnhem, Netherlands | |
More Information
| Responsible Party: | dr EH Gisolf, Rijnstate Hospital, Arnhem, the Netherlands |
| ClinicalTrials.gov Identifier: | NCT01353989 History of Changes |
| Other Study ID Numbers: |
Hepatitis A vaccination |
| Study First Received: | June 21, 2010 |
| Last Updated: | June 27, 2016 |
Keywords provided by Rijnstate Hospital:
|
hepatitis A vaccination elderly protection to hepatitis A after vaccination |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis A Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases |
Enterovirus Infections Picornaviridae Infections RNA Virus Infections Vaccines Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 26, 2017